Companiesandmarkets.com

Global asthma market to reach 159 million lifetime cases by 2022

Press Release   •   Jun 14, 2013 11:49 BST

Asthma is a chronic inflammatory lung disease that affects persons of all ages, but most commonly starts in childhood. It is a common long-term condition characterised by narrowing of the airways, leading to airflow limitation and airway hyper-responsiveness whenever the lungs come into contact with endogenous and exogenous irritants.

Exposure to irritants instigates a series of events, such as swelling of the airways, tightening of the respiratory muscles, and increased mucus production, leading to reduced airflow into the lungs.

Over 300 million people suffer from asthma, which translates to a drug market worth over $15 billion. While drugs to manage asthma have existed for several decades, pharmaceutical companies have developed faster acting and more effective products over the years.

The 2004 Global Initiative for Asthma (GINA) report estimated that 300 million people suffered from asthma worldwide, with the prevalence varying widely in different countries. However, recent trends show that the disparity is narrowing due to the rising prevalence of asthma in developing countries and the plateauing prevalence in developed countries.

Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment (Masoli et al., 2004; WHO, 2007).

In 2012, there were 135.28 million lifetime prevalent cases of asthma in the 10 major markets, with approximately 80.00 million cases in the US (41.90 million cases) and India (39.00 million cases) combined.

Some pharma manufacturers are due to see sales from their key brands in the area decline as patent expiries bite.

GlaxoSmithKline (GSK) will soon be hit by generic competition for Seretide (fluticasone propionate), while Merck & Co is expecting huge losses following the FDA's approval of first generic version of its asthma drug Singulair earlier this month. The drug made $4.4 billion during 2011.

Governments need to focus more on educating people about avoiding the risks for asthma and managing their symptoms, so they can live longer and more productive lives while reducing healthcare costs (de Marco et al., 2012).

For more information on the global asthma market, see the latest research: Global Asthma Market

Follow us on Twitter @CandMResearch


Companiesandmarkets.com issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.